Latest filings (excl ownership)
6-K
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
19 Apr 24
6-K
Report of Foreign Private Issuer
15 Apr 24
6-K
Report of Foreign Private Issuer
8 Apr 24
D
$1.75 mm in equity / options / securities to be acquired, sold $1.75 mm, 2 investors
3 Apr 24
424B5
Prospectus supplement for primary offering
22 Mar 24
6-K
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
21 Mar 24
6-K
Report of Foreign Private Issuer
20 Mar 24
6-K
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation
20 Mar 24
6-K
Report of Foreign Private Issuer
19 Mar 24
6-K
Report of Foreign Private Issuer
14 Mar 24
6-K
Report of Foreign Private Issuer
11 Mar 24
6-K
Report of Foreign Private Issuer
23 Feb 24
6-K
NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
12 Jan 24
6-K
Report of Foreign Private Issuer
29 Dec 23
6-K
Report of Foreign Private Issuer
22 Dec 23
6-K
Unaudited Interim Condensed Financial Statements
6 Dec 23
6-K
NLS Pharmaceutics Announces Election of Additional Board Members
4 Dec 23
6-K
Report of Foreign Private Issuer
4 Dec 23
6-K
Report of Foreign Private Issuer
1 Dec 23
6-K
Report of Foreign Private Issuer
16 Nov 23
6-K
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
25 Oct 23
6-K
Report of Foreign Private Issuer
25 Oct 23
6-K
Report of Foreign Private Issuer
13 Sep 23
6-K
Report of Foreign Private Issuer
30 Aug 23
6-K
Report of Foreign Private Issuer
20 Jul 23
6-K
NLS Pharmaceutics Releases the Results from its Annual General Meeting
3 Jul 23
6-K
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
14 Jun 23
6-K
Report of Foreign Private Issuer
9 Jun 23
6-K
Report of Foreign Private Issuer
24 May 23
6-K
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
8 May 23
6-K
Report of Foreign Private Issuer
5 May 23
20-F
2022 FY
Annual report (foreign)
5 May 23
6-K
Report of Foreign Private Issuer
2 May 23
NT 20-F
Notice of late annual filing (foreign)
1 May 23
6-K
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience® (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
27 Mar 23
6-K
Report of Foreign Private Issuer
21 Feb 23
6-K
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience® (Mazindol ER) for the Treatment of Narcolepsy
1 Feb 23
6-K
Report of Foreign Private Issuer
25 Jan 23
6-K
Report of Foreign Private Issuer
23 Jan 23
6-K
Report of Foreign Private Issuer
23 Jan 23
Latest ownership filings
SC 13G
Lind Global Fund II LP
27 Mar 24
SC 13G/A
YA II PN, Ltd.
12 Feb 24
SC 13G
Grisard Felix
24 Feb 23
SC 13G/A
Magnetic Rock Investment AG
14 Feb 23
SC 13G/A
Konofal Eric
14 Feb 23
SC 13G/A
Zwyer Alexander
13 Feb 23
SC 13G/A
YA II PN, Ltd.
3 Jan 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
16 Dec 22
SC 13G
Konofal Eric
24 Feb 22
SC 13G
Magnetic Rock Investment AG
18 Feb 22
SC 13G
Zwyer Alexander
14 Feb 22
SC 13G/A
YA II PN, Ltd.
11 Jan 22
SC 13G
YA II PN, Ltd.
8 Oct 21
SC 13G/A
HIRSCHMAN ORIN
17 Mar 21
SC 13G
HIRSCHMAN ORIN
4 Feb 21